Drug resistance interpretation: PR HIVDB 9.5.1 (2023-11-05)

PI Major Mutations: None PI Accessory Mutations: None

PR Other Mutations: 113V 2006 - G16E 2006 - K20KR cutts, a sen- E35D 2006 - M36H 2006 - M36H 2006 - R57K 2006 - R57K 2006 - R57K 2006 - H69R 2006 - 172M 2006 - L89M 2006 - 2006

Protease Inhibitors

Susceptible atazanavir/r (ATV/r) darunavir/r (DRV/r) Susceptible fosamprenavir/r (FPV/r) Susceptible indinavir/r (IDV/r) Susceptible lopinavir/r (LPV/r) Susceptible nelfinavir (NFV) Susceptible Susceptible saquinavir/r (SQV/r) tipranavir/r (TPV/r) Susceptible

PR comments

Mutation scoring: PR

Other

K20R is a highly polymorphic PI-selected accessory mutation that increases replication fitness in viruses with PI-resistance mutations.

No drug resistance mutations were found for PI.

Drug resistance interpretation: RT

NRTI Mutations: None

NNRTI Mutations: None

RT Other Mutations: EED ______ K11NT ______ K20R _____ K20R _____ K20R _____ K49R ______ K49R ______ K122E ______ K49R ______ K122E ______ K122E ______ K173S _______ K173S ______ K173S _______ K173S _______ K173S _______ K173S _______ K173S ________ K173S _______ K173S ________ K173S _______ K173S _______ K173S ________ K173S ________ K173S _______ K173S _______ K173S _______ K173S ________ K173S ________ K173S ________ K173S ________ K173S ________ K173S ________ K173S _________ K173S _________ K173S _________ K173S _________ K173S __________ K173S _________ K173S ____________ K173S ___________ K173S ____________ K173S ____________

Nucleoside Reverse Transcriptase Inhibitors

abacavir (ABC)

zidovudine (AZT)

Susceptible

stavudine (D4T)

didanosine (DDI)

emtricitabine (FTC)

lamivudine (3TC)

Susceptible

Susceptible

Susceptible

Susceptible

Susceptible

Susceptible

Susceptible

Non-nucleoside Reverse Transcriptase Inhibitors

doravirine (DOR)

efavirenz (EFV)

etravirine (ETR)

nevirapine (NVP)

rilpivirine (RPV)

Susceptible

Susceptible

Susceptible

RT comments

Mutation scoring: RT

Other

V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.

No drug resistance mutations were found for NRTL

No drug resistance mutations were found for NNRTI.

HIVDB 9.5.1 (2023-11-05)

HIVDB 9.5.1 (2023-11-05)

HIVDB 9.5.1 (2023-11-05)